Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Where We Are Indexed
Past Issue Archives
Clinical Communication
In Review
Editorial Board
Information for Authors
Author Form

Reprints, Permissions, & Copyright
Site Map
BACK ISSUE articles are $15 each.
International credit cards NOT accepted.

JCOM Paid Subscribers
user name:
Forgot password?

JCOM Abstract

J Clin Outcomes Manage 
2013 Sep;20(9):400-406
Off-label use of Ondansetron in hospitalized medical patients: prevalence, patterns, and predictors
Hartley S, Kuhn L, Valley S, Fallouh N, Dussan KB, Judd S, Murphy SL, Saint S, Chopra V

ABSTRACT Background: Ondansetron is frequently prescribed in hospitalized patients for nausea and vomiting. However, the Food and Drug Administration (FDA) has approved this agent only for prophylaxis of nausea and emesis related to chemo- and radiation therapy or postoperative states. Objective: To determine prevalence and predictors of off-label ondansetron use in hospitalized adult patients. Methods: Retrospective cohort study of 158 hospitalized medical patients who received non-FDA-approved ondansetron; treatment with promethazine or prochlorperazine in 151 patients was considered standard treatment. Patterns of non-FDA-approved use were analyzed using descriptive statistics. Multivariable logistic regression models were then fit to identify predictors of such use. Results: In hospitalized medical patients, ondansetron as first-line treatment for nausea outside of FDA-approved indications was 5 times more prevalent than standard therapy (4169 doses versus 750 doses). In a random sample, patients treated with ondansetron were older (54.6 versus 48.8 years, P < 0.01), more likely to be hypertensive (50.6% vs. 39.7%, P = 0.05), and less frequently prescribed multiple antiemetics at the time of admission (32.3% vs. 43.7%, P = 0.04). Receipt of prochlorperazine or promethazine in the emergency department (ED) was associated with decreased likelihood of receiving non-FDA-approved ondansetron therapy as the first antiemetic after admission (odds ratio 0.27, 95% confidence interval 0.110.66). Conclusions: Although ondansetron therapy for non-FDA approved indications is highly prevalent in hospitalized medical adults, use of standard anti-nausea treatment in the ED may curtail this practice. Implementing policies for targeting use of medications in the ED may significantly influence inpatient practice.

Original Research

Search the Turner White index to find abstracts of articles published in JCOM.

New issues are posted one month following publication of the printed journal.

View past issue archives:    2013    2012    2011    2010    2009    2008    2007
   2006    2005    2004    2003     2002     2001     2000     1999

Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2018, Turner White Communications
Updated 1/20/14 • jdw